Pure Global
NCT06108544

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
Takeda·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Plaque Psoriasis
Drug/Device/Intervention
TAK-279
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Takeda
Location
East Windsor, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Nov 06, 2023
End date
Jun 10, 2026
Enrollment
1000 participants
Primary outcome

Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against Placebo,Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16 Comparing TAK-279 Against Placebo

Summary

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to
 placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be
 assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a
 placebo). Participants will be in the study for up to 69 weeks.

ICD-10 classifications
PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06108544
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06108544 through Pure Global AI's free database. This Phase 3 trial is sponsored by Takeda and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.